Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting

Kokkinou, Michelle; Beishon, Lucy; Smailagic, Nadja; Noel-Storr, Anna; Hyde, Chris; Ukoumunne, Obioha C; Hayen, Anja; Desai, Meera; Ashok, Abhishekh Hulegar; Paul, Eleanor J.; Georgopoulou, Aikaterini; Casoli, Tiziana; Quinn, Terry; Ritchie, Craig W.

doi:10.1002/14651858.cd010945.pub2

Cited by 17 publications

(6 citation statements)

References 131 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Especially episodic memory tests of delayed free and cued recall represent highly sensitive measures of memory decline in the typical presentation of AD. Apart from cerebrospinal fluid Ab42 concentrations 21 , medial temporal lobe atrophy is most likely furthest through validation 6 , but must, at present, also be considered insufficient as a single biomarker 22 .…”

Section: Introductionmentioning

confidence: 99%

Single-value scores of memory-related brain activity reflect dissociable neuropsychological and anatomical signatures of neurocognitive aging

Richter

Soch

Kizilirmak

et al. 2022

Preprint

View full text Add to dashboard Cite

Memory-related functional magnetic resonance imaging (fMRI) activations show characteristic age-related differences, but their use as biomarkers for neurocognitive aging and ultimately dementia risk states is complicated by their high dimensionality. Here, we make a step towards biomarker validation of two single-value scores reflecting deviations from prototypical fMRI activity patterns of young adults computed for the novelty and subsequent memory contrasts from an incidental visual memory encoding fMRI experiment. To optimize procedures of fMRI phenotyping we compared associations of the scores with dementia-relevant variables: cognitive performance in multiple domains and brain structure in 153 healthy older adults. While novelty-driven scores specifically correlated with hippocampus-dependent memory performance, memory-driven scores additionally correlated with global cognition and medial temporal gray matter volumes. Our results reveal complementary associations of reductionist fMRI-based scores with cognitive and structural measures relevant for future validation studies in (pre-)clinical samples, paving the way towards biomarker validation.

show abstract

Section: Introductionmentioning

confidence: 99%

Single-value scores of memory-related brain activity reflect dissociable neuropsychological and anatomical signatures of neurocognitive aging

Richter

Soch

Kizilirmak

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…There is significant evidence in favour of using CSF levels of phosphorylated tau (Ptau), total tau (Ttau), and neurofilament light (NFL) as biomarkers for preclinical AD detection (45). In isolation of other risk factor analysis, CSF biomarkers yield reasonable sensitivity but poor specificity for predicting progression from preclinical AD to a clinical dementia syndrome, highlighting the need to embed such biomarker assessments in multifaceted risk algorithms (46)(47)(48). The extraction of CSF through lumbar puncture (LP) is an invasive procedure and will not be suitable for all patients, but its benefits should not be overlooked.…”

Section: Cerebrospinal Fluid and Blood Biomarkersmentioning

confidence: 99%

The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland

et al. 2021

View full text Add to dashboard Cite

In order to address the oft-cited societal, economic, and health and social care impacts of neurodegenerative diseases, such as Alzheimer’s disease, we must move decisively from reactive to proactive clinical practice and to embed evidence-based brain health education throughout society. Most disease processes can be at least partially prevented, slowed, or reversed. We have long neglected to intervene in neurodegenerative disease processes, largely due to a misconception that their predominant symptom – cognitive decline – is a normal, age-related process, but also due to a lack of multi-disciplinary collaboration. We now understand that there are modifiable risk factors for neurodegenerative diseases, that successful management of common comorbidities (such as diabetes and hypertension) can reduce the incidence of neurodegenerative disease, and that disease processes begin (and, crucially, can be detected, reduced, and delayed, prevented, or treated) decades earlier in life than had previously been appreciated. Brain Health Scotland, established by Scottish Government and working in partnership with Alzheimer Scotland, propose far-reaching public health and clinical practice approaches to reduce neurodegenerative disease incidence. Focusing here on Brain Health Scotland’s clinical offerings, we present the Scottish Model for Brain Health Services. To our knowledge, the Scottish Model for Brain Health, built on foundations of personalised risk profiling, targeted risk reduction and prevention, early disease detection, equity of access, and harnessing comprehensive data to assist in clinical decision-making, marks the first example of a nationwide approach to overhauling clinical, societal, and political approaches to the prevention, assessment, and treatment of neurodegenerative disease.

show abstract

“…Dementia is a clinical syndrome triggered by many differing pathologies, mainly including Alzheimer’s disease dementia (AD), vascular dementia (VD) and mixed AD/VD, dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) ( Kokkinou et al, 2021 ). In 2030, it was estimated that there will be about 75.6 million people with dementia and the numbers are projected to rise to 131.5 million by 2050 ( Ijaopo, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

“…In 2020, Bai et al demonstrated new potential proteins and molecular networks in brain tissue, cerebrospinal fluid during the progression of AD through proteomics based on mass spectrometry (MS) and multilayer omics methods, and further identified them in mouse models ( Bai et al, 2020 ). However, to date, there are no valid options for the earliest possible and reliable diagnosis, but so far, these candidate biomarkers have only been established by AD, mostly requiring invasive and expensive procedures ( Maul et al, 2020 ; Kokkinou et al, 2021 ). The clinical diagnosis of VD still depends on imaging criteria and there is no specific biochemical marker.…”

Section: Introductionmentioning

confidence: 99%

Urinary protein biomarkers based on LC–MS/MS analysis to discriminate vascular dementia from Alzheimer’s disease in Han Chinese population

Chen

Xiao

et al. 2023

Front. Aging Neurosci.

View full text Add to dashboard Cite

ObjectiveThis study aimed to identify the potential urine biomarkers of vascular dementia (VD) and unravel the disease-associated mechanisms by applying Liquid chromatography tandem-mass spectrometry (LC–MS/MS).MethodsLC–MS/MS proteomic analysis was applied to urine samples from 3 groups, including 14 patients with VD, 9 patients with AD, and 21 normal controls (NC). By searching the MS data by Proteome Discoverer software, analyzing the protein abundances qualitatively and quantitatively, comparing between groups, combining bioinformatics analysis using Gene Ontology (GO) and pathway crosstalk analysis using Kyoto Encyclopedia of Genes and Genomes (KEGG), and literature searching, the differentially expressed proteins (DEPs) of VD can be comprehensively determined at last and were further quantified by receiver operating characteristic (ROC) curve methods.ResultsThe proteomic findings showed quantitative changes in patients with VD compared to patients with NC and AD groups; among 4,699 identified urine proteins, 939 and 1,147 proteins displayed quantitative changes unique to VD vs. NC and AD, respectively, including 484 overlapped common DEPs. Then, 10 unique proteins named in KEGG database (including PLOD3, SDCBP, SRC, GPRC5B, TSG101/STP22/VPS23, THY1/CD90, PLCD, CDH16, NARS/asnS, AGRN) were confirmed by a ROC curve method.ConclusionOur results suggested that urine proteins enable detection of VD from AD and VC, which may provide an opportunity for intervention.

show abstract

Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting

Abstract: Plasma and cerebrospinal fluid ABeta42 for the di erential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.

Cited by 17 publications

References 131 publications

Single-value scores of memory-related brain activity reflect dissociable neuropsychological and anatomical signatures of neurocognitive aging

Single-value scores of memory-related brain activity reflect dissociable neuropsychological and anatomical signatures of neurocognitive aging

The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland

Urinary protein biomarkers based on LC–MS/MS analysis to discriminate vascular dementia from Alzheimer’s disease in Han Chinese population

Contact Info

Product

Resources

About